How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
45
BDTX Quote, Financials, Valuation and Earnings
Last price:
$2.49
Seasonality move
:
-5.14%
Day range:
$2.45 - $2.64
52-week range:
$1.20 - $4.94
Dividend yield:
0%
P/E ratio:
6.86x
P/S ratio:
2.03x
P/B ratio:
1.12x
Volume:
805.5K
Avg. volume:
918.1K
1-year change:
-1.19%
Market cap:
$141.9M
Revenue:
--
EPS (TTM):
$0.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
-- | -$0.20 | -86.61% | -93.68% | $9.29 |
|
BNGO
Bionano Genomics, Inc.
|
$9.1M | -$0.78 | 29.66% | -82.39% | $7.50 |
|
EBS
Emergent BioSolutions, Inc.
|
$295M | $0.11 | 23.76% | -94.67% | $13.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PBYI
Puma Biotechnology, Inc.
|
$55M | $0.12 | 16.12% | -41.13% | $5.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
$2.49 | $9.29 | $141.9M | 6.86x | $0.00 | 0% | 2.03x |
|
BNGO
Bionano Genomics, Inc.
|
$1.30 | $7.50 | $13.2M | -- | $0.00 | 0% | 0.15x |
|
EBS
Emergent BioSolutions, Inc.
|
$11.34 | $13.50 | $595.6M | 8.76x | $0.00 | 0% | 0.80x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.86 | $0.85 | $234.7M | 3.12x | $0.80 | 0% | 3.61x |
|
PBYI
Puma Biotechnology, Inc.
|
$6.48 | $5.00 | $326.5M | 8.75x | $0.00 | 0% | 1.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
13.49% | 5.149 | 9.11% | 8.72x |
|
BNGO
Bionano Genomics, Inc.
|
25.67% | -0.584 | 103.34% | 1.58x |
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.542 | 144.36% | 2.93x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.733 | 15.34% | 1.57x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
-$86K | -$11M | 15.62% | 18.5% | 77.9% | -$7.9M |
|
BNGO
Bionano Genomics, Inc.
|
$3.4M | -$8.5M | -58.02% | -84.77% | -115.9% | -$5.9M |
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Black Diamond Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns BDTX or BNGO?
Bionano Genomics, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of -115.42%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Bionano Genomics, Inc.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M BNGOBionano Genomics, Inc.45.75% -$1.59 $67M -
What do Analysts Say About BDTX or BNGO?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.29, signalling upside risk potential of 272.92%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 476.92%. Given that Bionano Genomics, Inc. has higher upside potential than Black Diamond Therapeutics, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Black Diamond Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 BNGOBionano Genomics, Inc.1 0 0 -
Is BDTX or BNGO More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.396, which suggesting that the stock is 239.585% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.141, suggesting its more volatile than the S&P 500 by 14.145%.
-
Which is a Better Dividend Stock BDTX or BNGO?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or BNGO?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Bionano Genomics, Inc. quarterly revenues of $7.4M. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 6.86x while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.03x versus 0.15x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.03x 6.86x -- -$8.5M BNGOBionano Genomics, Inc.0.15x -- $7.4M -$8.5M
-
Which has Higher Returns BDTX or EBS?
Emergent BioSolutions, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 22.16%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Emergent BioSolutions, Inc.'s return on equity of 14.25%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B -
What do Analysts Say About BDTX or EBS?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.29, signalling upside risk potential of 272.92%. On the other hand Emergent BioSolutions, Inc. has an analysts' consensus of $13.50 which suggests that it could grow by 19.05%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 EBSEmergent BioSolutions, Inc.2 0 0 -
Is BDTX or EBS More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.396, which suggesting that the stock is 239.585% more volatile than S&P 500. In comparison Emergent BioSolutions, Inc. has a beta of 2.300, suggesting its more volatile than the S&P 500 by 129.997%.
-
Which is a Better Dividend Stock BDTX or EBS?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Emergent BioSolutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or EBS?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Emergent BioSolutions, Inc. quarterly revenues of $231.1M. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Emergent BioSolutions, Inc.'s net income of $51.2M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 6.86x while Emergent BioSolutions, Inc.'s PE ratio is 8.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.03x versus 0.80x for Emergent BioSolutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.03x 6.86x -- -$8.5M EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M
-
Which has Higher Returns BDTX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of -255.85%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BDTX or NBY?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.29, signalling upside risk potential of 272.92%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -54.3%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BDTX or NBY More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.396, which suggesting that the stock is 239.585% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock BDTX or NBY?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or NBY?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 6.86x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.03x versus 3.61x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.03x 6.86x -- -$8.5M NBYNovaBay Pharmaceuticals, Inc.3.61x 3.12x $521K -$1.3M
-
Which has Higher Returns BDTX or PBYI?
Puma Biotechnology, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 16.24%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About BDTX or PBYI?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.29, signalling upside risk potential of 272.92%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -22.84%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is BDTX or PBYI More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.396, which suggesting that the stock is 239.585% more volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.747%.
-
Which is a Better Dividend Stock BDTX or PBYI?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or PBYI?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 6.86x while Puma Biotechnology, Inc.'s PE ratio is 8.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.03x versus 1.53x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.03x 6.86x -- -$8.5M PBYIPuma Biotechnology, Inc.1.53x 8.75x $54.5M $8.8M
-
Which has Higher Returns BDTX or PTN?
Palatin Technologies has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of --. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About BDTX or PTN?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.29, signalling upside risk potential of 272.92%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Black Diamond Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Black Diamond Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 PTNPalatin Technologies0 0 0 -
Is BDTX or PTN More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.396, which suggesting that the stock is 239.585% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock BDTX or PTN?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or PTN?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is higher than Palatin Technologies's net income of --. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 6.86x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.03x 6.86x -- -$8.5M PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
